Axitinib dose titration: What's the limiting factor?

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages 1152-1154

  Buti, Sebastiano ^a   Porta, Camillo ^b,c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c GION Gruppo Italiano di Oncologia Nefrologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; PLACEBO; SORAFENIB;

CANCER PATIENT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EXPOSURE; HUMAN; KIDNEY METASTASIS; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS;

EID: 84886730266     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70489-3     Document Type: Letter

References (10)

1. Van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17:620-629.
2. Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 2013, 53:491-504.
3. Amato R, Zhai J, Willis J, Saxena S, De Foe M A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2012, 10:153-158.
4. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
5. Gore ME, Jones RJ, Ravaud A, et al. Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 4609.
6. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012, 30:1371-1377.
7. Buti S, Donini M, Lazzarelli S, Passalacqua R A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. Acta Biomed 2012, 83:88-94.
8. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes in metastatic renal cell carcinoma patients treated with alternative sunitinib schedules. J Urol 2013, published online Sept 6. 10.1016/j.juro.2013.08.090.
9. Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013, published online Oct 18. http://dx.doi.org/10.1016/S1470-2045(13)70464-9.
10. Hutson TE, Gallardo J, Lesovoy V, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013, in press.